The use of drug calendars for the diagnosis of cutaneous drug eruptions in the age of electronic medical records

A morbilliform drug eruption is the most common condition leading to a dermatology consultation for a patient in the hospital. Timing is an important diagnostic tool since the onset of a skin rash usually takes place within days-to-weeks of the start of the implicated drug. A comprehensive, thorough, and reliable drug history by the clinician is essential. Therefore, to assist in the task of determining the causative medication of a new skin rash in a hospitalized patient, the creation of a drug calendar is recommended. The development of an electronic version of the drug calendar offers several benefits over the manual version. As the use of electronic medical records continues to become the standard in medicine, the electronic drug calendar will serve as an invaluable tool for the diagnosis of drug hypersensitivity

Human-Machine Interfacing via Epidermal Electronic Systems

Surface electromyography (EMG) is rapidly becoming a viable control source for interfacing with machines. By measuring the electric potential generated by the contractions of skeletal muscles, systems can be controlled with a mere flick of the wrist, allowing intuitive and versatile control to the wielder. As sensors and classification algorithms become more sophisticated, EMG control has increasing potential to revolutionize the way we interact with and utilize technology. Prosthetics in particular have benefited the most from these recent advances, with one research team successfully returning ambulation to a leg amputee last year. However, this technology is not yet suitable for practical use, as implementations often require bulky hardware and is limited by the complexities of the software. To amend these issues and facilitate further research in this field, we propose a consolidated solution that will handle the acquisition and classification of an EMG input while providing protocols to interface with an external system. Where most setups are cumbersome and impractical, usually requiring a piece of dedicated hardware for each step in the signal chain, we have made our system as small and cost-effective as possible. By consolidating our solution onto a single circuit board with bluetooth integration, we will maximize portability and afford researchers flexibility when working with our system. This portability will allow our device to be placed in close proximity to the EMG sensors to transmit the signal wirelessly to a central hub, which will process it further. Here the central hub will classify the waveform and map it to a definitive command that can be used to interface with an external system. This will abstract the classification aspect away from the developer, simplifying the process and allowing them to focus on what they are trying to accomplish. Our system will also allow for further extension by being robust enough to handle multiple EMG inputs and allowing researchers to easily configure the device for their purposes. To accommodate future advances in classification algorithms or future improvements to the system itself, we will also provide frameworks that will allow researchers and developers to program the device themselves. By giving researchers the tools to quickly implement this technology, we allow them to focus on other aspects of what they are trying to build instead of worrying about the technicalities that go into designing a system like this. Further development in this field will give us unprecedented ways to interact with the world around us and change how we utilize technology. Given this technology’s proclivity towards those who are disabled, our project has the potential to drastically improve the quality of life for the unfortunate as well.https://scholarscompass.vcu.edu/capstone/1040/thumbnail.jp

High Fidelity Tape Transfer Printing Based On Chemically Induced Adhesive Strength Modulation

Transfer printing, a two-step process (i.e. picking up and printing) for heterogeneous integration, has been widely exploited for the fabrication of functional electronics system. To ensure a reliable process, strong adhesion for picking up and weak or no adhesion for printing are required. However, it is challenging to meet the requirements of switchable stamp adhesion. Here we introduce a simple, high fidelity process, namely tape transfer printing(TTP), enabled by chemically induced dramatic modulation in tape adhesive strength. We describe the working mechanism of the adhesion modulation that governs this process and demonstrate the method by high fidelity tape transfer printing several types of materials and devices, including Si pellets arrays, photodetector arrays, and electromyography (EMG) sensors, from their preparation substrates to various alien substrates. High fidelity tape transfer printing of components onto curvilinear surfaces is also illustrated

Translational Oncogenomics and Human Cancer Interactome Networks

An overview of translational, human oncogenomics, transcriptomics and cancer interactomic networks is presented together with basic concepts and potential, new applications to Oncology and Integrative Cancer Biology. Novel translational oncogenomics research is rapidly expanding through the application of advanced technology, research findings and computational tools/models to both pharmaceutical and clinical problems. A self-contained presentation is adopted that covers both fundamental concepts and the most recent biomedical, as well as clinical, applications. Sample analyses in recent clinical studies have shown that gene expression data can be employed to distinguish between tumor types as well as to predict outcomes. Potentially important applications of such results are individualized human cancer therapies or, in general, ‘personalized medicine’. Several cancer detection techniques are currently under development both in the direction of improved detection sensitivity and increased time resolution of cellular events, with the limits of single molecule detection and picosecond time resolution already reached. The urgency for the complete mapping of a human cancer interactome with the help of such novel, high-efficiency / low-cost and ultra-sensitive techniques is also pointed out

Stretchable electronics for artificial skin

Postprint (published version

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up.

PurposeIn the initial PALOMA-2 (NCT01740427) analysis with median follow-up of 23 months, palbociclib plus letrozole significantly prolonged progression-free survival (PFS) in women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) [hazard ratio (HR) 0.58; P < 0.001]. Herein, we report results overall and by subgroups with extended follow-up.MethodsIn this double-blind, phase 3 study, post-menopausal women with ER+/HER2- ABC who had not received prior systemic therapy for their advanced disease were randomized 2:1 to palbociclib-letrozole or placebo-letrozole. Endpoints include investigator-assessed PFS (primary), safety, and patient-reported outcomes (PROs).ResultsAfter a median follow-up of approximately 38 months, median PFS was 27.6 months for palbociclib-letrozole (n = 444) and 14.5 months for placebo-letrozole (n = 222) (HR 0.563; 1-sided P < 0.0001). All subgroups benefited from palbociclib treatment. The improvement of PFS with palbociclib-letrozole was maintained in the next 2 subsequent lines of therapy and delayed the use of chemotherapy (40.4 vs. 29.9 months for palbociclib-letrozole vs. placebo-letrozole). Safety data were consistent with the known profile. Patients' quality of life was maintained.ConclusionsWith approximately 15 months of additional follow-up, palbociclib plus letrozole continued to demonstrate improved PFS compared with placebo plus letrozole in the overall population and across all patient subgroups, while the safety profile remained favorable and quality of life was maintained. These data confirm that palbociclib-letrozole should be considered the standard of care for first-line therapy in patients with ER+/HER2- ABC, including those with low disease burden or long disease-free interval. Sponsored by Pfizer; ClinicalTrials.gov: NCT01740427